Otsuka Pharmaceutical Deal History & Licensing Activity
Otsuka Pharmaceutical is a large pharma headquartered in Japan. Over the past three years, Otsuka Pharmaceutical has been involved in 7 licensing and acquisition transactions, with a primary focus on Small Molecules (3 deals). The company currently has 50 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
3
Active Trials
50
Top Modality
Small Molecules
Focus Area
CNS Disorders
Otsuka Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Otsuka Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| TSND-201 (methylone) | Transcend Therapeutics | Small Molecules | Unknown | acquisition | Mar 27, 2026 |
| MTX240 | Biodexa Pharmaceuticals PLC | Small Molecules | Preclinical | license | Feb 4, 2026 |
| 4D-150 | Otsuka | Gene Therapy | Phase 3 | license | Oct 30, 2025 |
Otsuka Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Otsuka Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Otsuka Pharmaceutical Strategic Signals
Key indicators of Otsuka Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Otsuka Pharmaceutical Clinical Pipeline
Otsuka Pharmaceutical has 50 active clinical trials across 8 development phases.
2
Not Applicable
8
Unknown
1
Phase 4
9
Phase 1
2
Phase 1/2
7
Phase 2
3
Phase 2/3
18
Phase 3
See How Your Asset Matches Otsuka Pharmaceutical's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Otsuka Pharmaceutical Licensing & Deal Activity
Otsuka Pharmaceutical is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, Otsuka Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Otsuka Pharmaceutical include CNS Disorders (18 deals and trials), Autoimmune (7 deals and trials), Rare Disease (5 deals and trials), and Renal (4 deals and trials). In terms of modality, Otsuka Pharmaceutical has shown particular interest in small molecules, small molecules, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Otsuka Pharmaceutical and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Otsuka Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.